1. Scrip
  2. >>Business

Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?

Tally Is Behind Recent Years

 
• By Andrew McConaghie

Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.

Pfizer capsules
Pfizer has invested some of its COVID-19 windfall in M&A, most notably the $11.6bn buyout of Biohaven. • Source: Shutterstock

Many pharma market analysts had predicted 2022 was going to be a bumper year for mergers and acquisitions, but ten months in, that buying bonanza has yet to materialize.

A new analysis from SVB Securities shows there have been 16 merger and acquisitions agreed by the top 20 biopharma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.